The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail

Cuvitru 200 mg/ml solution for subcutaneous injection

Baxalta Innovations GmbHPA2004/008/001

Main Information

Trade NameCuvitru 200 mg/ml solution for subcutaneous injection
Active SubstancesHuman normal immunoglobulin
Dosage FormSolution for injection
Licence HolderBaxalta Innovations GmbH
Licence NumberPA2004/008/001

Group Information

ATC CodeJ06BA01 immunoglobulins, normal human, for extravascular adm.


License statusAuthorised
Licence Issued08/07/2016
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusMarketed


Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available
« Back